• 3 July 2017

    Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, announces that GlaxoSmithKline (GSK) has selected a third target as part of their ongoing oncology discovery collaboration for multiple novel targets not addressable with antibody-based technologies. Immunocore will generate a novel ImmTAC® molecule against the selected target which is relevant in multiple cancers.

  • 28 June 2017

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that world-renowned diabetes experts Professor Mark Cooper, Head of the Department of Diabetes at Monash University, and Professor Jonathan Shaw, Deputy Director (Clinical and Population Health) at the Baker Heart and Diabetes Institute in Melbourne, Australia, will lead the conduct of a phase 2 clinical trial to evaluate the efficacy and safety of the Company’s lead product candidate, GKT831, in patients with type 1 diabetes and kidney disease (diabetic kidney disease).

  • 27 June 2017

    Genkyotex (Euronext Paris & Brussels: FR00011790542 –, a biopharmaceutical company and the leader in NOX therapies, announced today that it has begun enrolling patients into the Company’s Phase 2 clinical trial of GKT831, its NOX1 and NOX4 enzymes inhibitor, in primary biliary cholangitis (PBC). Enrollment initiation at the first investigational center in the U.S. took place following regulatory clearance by the U.S. Food & Drug Administration and local Institutional Review Board.  Dosing of the first patient is expected shortly.

  • 26 June 2017

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKI) as novel, locally-acting medicines for the treatment of chronic inflammatory gastrointestinal and ocular diseases, today announces the successful completion of three clinical studies TV02, TV03 and TV04, which are all on course to report later in the year. 

  • 21 June 2017

    InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT – a phase IIb dose optimisation study with the drug candidate cobitolimod. Cobitolimod is a first in class immunotherapeutic, which is being developed for the treatment of moderate to severe active ulcerative colitis.